Jim Cramer Discussed The Iran Ceasefire & Commented On These 19 Stocks

7. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 137

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s favorite stocks. Its shares are up by 28% over the past year but are down by 13% year-to-date. Guggenheim trimmed Eli Lilly and Company (NYSE:LLY)’s share price target to $1,163 from $1,168 and kept a Buy rating on the shares on March 30th ahead of the pharmaceutical company’s Q1 2026 earnings. Guggenheim’s coverage came after RBC Capital had reiterated an Outperform rating and a $1,250 share price target for Eli Lilly and Company (NYSE:LLY) on March 16th. As part of its coverage, RBC remarked that a rival firm’s treatment appeared to mimic Eli Lilly and Company (NYSE:LLY)’s drug and did not demonstrate any superior performance. The shares closed 3.8% higher on April 1st after the Food and Drug Administration (FDA) approved the firm’s weight loss pill, Foundayo. The day after, Novo Nordisk claimed that its weight loss pill was better than Eli Lilly and Company (NYSE:LLY)’s. Cramer discussed the claim:

“Look, if you wanted a pill and you wanted to be able to take it when you want, and you don’t have to worry about taking it with the food and stuff, that’s a, Lilly’s got that going. Remember, the main thing that Lilly has got going is they’re not gonna run out, that they have spent a fortune [on manufacturing]. David Ricks is forward thinking and Jensen Huang wants to do something with a pharmaceutical company, it’s going to be Ricks. And then Ricks says yes. He’s a big thinker. He bought this Centessa the other day, it looks like it’s just for narcolepsy but jeez, it could be the answer to a lot of mood disorders.”